Jan 08, 2024
Compugen to Receive $10 Million Milestone Payment Following Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Jun 01, 2020
Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
May 27, 2020
Compugen Doses First Patient in COM701 Phase 1 Monotherapy Expansion Cohort
May 20, 2020
Evogene Launches Its New Branding to Reflect the Company's Expanded Vision and New Business Model
May 06, 2020
Compugen Reports First Quarter 2020 Results
Apr 27, 2020
Compugen Presents Data Update From Ongoing Phase 1 Trial of COM701 at the 2020 AACR Virtual Annual Meeting
Apr 23, 2020
Compugen to Release First Quarter 2020 Results on Wednesday, May 6, 2020
Apr 22, 2020
Compugen Expands Intellectual Property Portfolio for COM701 With New European Composition of Matter Patent
Apr 20, 2020
Compugen Announces Publication of BAY 1905254 Preclinical Data in Cancer Immunology Research
Apr 14, 2020
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the 2020 AACR Virtual Annual Meeting
Apr 06, 2020
Compugen Announces First Patient Dosed in COM902 Phase 1 Trial for Patients With Advanced Malignancies
Mar 17, 2020
Compugen Announces Closing of $75 Million Public Offering of Ordinary Shares
Mar 17, 2020
Medicxi Bolsters and Expands Team with Senior Industry Leaders
Mar 12, 2020
Compugen Announces Pricing of $75 Million Public Offering of Ordinary Shares
Mar 11, 2020
Compugen Announces Commencement of Public Offering of Ordinary Shares
Mar 09, 2020
Compugen Announces Updated Clinical Data from Ongoing COM701 Phase 1 Study
Feb 20, 2020
Compugen Reports Fourth Quarter and Full Year 2019 Results
Feb 20, 2020
Compugen Announces Phase 1/2 Triple Combination Study to Evaluate COM701 in Combination With Bristol-Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
Feb 07, 2020
Compugen Presents Update on COM701 Phase 1 Trial at ASCO-SITC Clinical Immuno-oncology Symposium
Feb 04, 2020
Compugen Announces New U.S. Patent for Methods of Screening for Anti-PVRIG Antibodies